Drug Profile


Alternative Names: CX 691; ORG 24448

Latest Information Update: 18 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cortex Pharmaceuticals; University of California at Irvine
  • Developer Organon
  • Class Antidepressants; Antipsychotics; Neuroprotectants; Nootropics; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action AMPA receptor agonists; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder; Schizophrenia

Most Recent Events

  • 19 Nov 2007 Organon has been acquired by Schering-Plough
  • 17 Oct 2007 Final efficacy data from a clinical trial in healthy elderly volunteers presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
  • 17 Jan 2001 Phase-I clinical trials for Psychotic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top